← Back to Clinical Trials
Recruiting NCT05706194

NCT05706194 Early Neuroprognostication After OHCA

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05706194
Status Recruiting
Phase
Sponsor Lund University
Condition Cardiac Arrest
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2023-10-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL
Interventions
Early neurological prognostication with biomarkers, EEG and CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2023-10-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective observational substudy of the STEPCARE trial ClinicalTrials.gov Identifier: NCT05564754) with the aim to examine whether prognostication of neurological outcome after cardiac arrest can be performed earlier than the 72 h time-point recommended by guidelines today.

Eligibility Criteria

Inclusion Criteria: Adult cardiac arrest patients with an out-of-hospital cardiac arrest of non-traumatic cause treated at hospitals recruiting patients to the STEPCARE neuroprognostication substudy. Other inclusion criteria include: * a minimum of 20 minutes without chest compressions * Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of \<4) or being intubated and sedated because of agitation after sustained ROSC * Eligible for intensive care without restrictions or limitations * Inclusion within 4 hours of ROSC Exclusion Criteria: * On ECMO prior to randomisation * Pregnancy * Suspected or confirmed intracranial hemorrhage * Previously randomised in the STEPCARE trial * Patients with limitations in level-of-care due to for example generalized malignancy

Contact & Investigator

Central Contact

Marion Moseby-Knappe, MD, PhD

✉ marion.moseby_knappe@med.lu.se

📞 00464671000

Principal Investigator

Niklas Nielsen, MD, PhD

STUDY CHAIR

Lund University

Frequently Asked Questions

Who can join the NCT05706194 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05706194 currently recruiting?

Yes, NCT05706194 is actively recruiting participants. Contact the research team at marion.moseby_knappe@med.lu.se for enrollment information.

Where is the NCT05706194 trial being conducted?

This trial is being conducted at Helsinki, Finland, Berlin, Germany, Helsingborg, Sweden, Lund, Sweden.

Who is sponsoring the NCT05706194 clinical trial?

NCT05706194 is sponsored by Lund University. The principal investigator is Niklas Nielsen, MD, PhD at Lund University. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology